Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will be presenting at Rodman & Renshaw’s 17th Annual Global Investment Conference, which is being held on September 8-10, 2015 at the St. Regis Hotel in New York.

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=930141

Leave a comment

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of Paul J. Merrigan as Chief Commercial Officer. Mr. Merrigan will be responsible for leading Catalyst’s marketing, sales and commercial operations. He replaces Richard Daly, who served as interim Chief Commercial Officer during the search. Mr. Daly will continue in his role as a member of the board of directors.

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=927856

Leave a comment

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the second quarter and six months ended June 30, 2015.

“This quarter we have been working diligently to advance regulatory and commercial affairs and are pleased with the initiation of our rolling NDA submission to the FDA for Firdapse® for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS),” said Patrick J. McEnany, Catalyst’s Chief Executive Officer. “We expect to complete our submission during Q4, putting us on schedule for a potential approval by the middle of 2016. We are working on a pathway to include certain types of congenital myasthenic syndromes (CMS) in the initial label, in addition to LEMS. Additionally, we are on schedule with our key commercial strategic imperatives to support the successful launch of Firdapse®.”

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=926975

Leave a comment

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the initiation of a rolling submission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for Firdapse® for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). Firdapse® has received Breakthrough Therapy Designation from the FDA for the treatment of LEMS, as well as orphan drug designations for LEMS and congenital myasthenic syndromes (CMS).

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=923310

Leave a comment

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of Gary Ingenito, M.D., Ph.D, as Chief Medical Officer. Dr. Ingenito has more than 25 years of experience leading pharmaceutical development for drugs and biologics. In this new role, he will oversee all clinical development programs, medical affairs, regulatory and other related functions. Dr. Ingenito will report to Dr. Steven Miller, Catalyst’s Chief Operating Officer and Chief Scientific Officer. Following Dr. Ingenito’s joining Catalyst, the current Chief Medical Officer, Charles Gorodetzky, M.D., Ph.D, will continue to serve as a consultant to the company.

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=920027

Leave a comment

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the company has been added to the Russell 2000®, the Russell 3000® and Russell Global Indexes, following Russell’s annual reconstitution on June 26, according to a preliminary list of additions posted June 12, 2015 on the FTSE Russell website.

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=919884

Leave a comment

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced top-line results in an open-label, proof-of-concept trial of CPP-109 (vigabatrin) used to treat patients suffering from Tourette’s Disorder (TD) that were refractory to all other previous treatments. One of four patients demonstrated a very clear, clinically significant reduction in tics, and two others showed about a 25% reduction in tics, but without subjective clinical improvement.

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=919254

Leave a comment

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced the appointment of Richard J. Daly to the position of interim Chief Commercial Officer. A member of Catalyst’s board of directors, Daly, 54, will lead pre-commercial activities for Firdapse® while the company conducts a search for an executive to run commercial operations. He replaces David Muth, who has left the company to pursue other opportunities.

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=915333

Leave a comment

Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that the Company will be presenting at the Jefferies 2015 Healthcare Conference, in New York. Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer/COO, will provide an overview of the Company and its key programs on Tuesday, June 2 at 11:00 am ET. The Company’s presentation materials will be available on the “Investors” section of the Company’s website, www.catalystpharma.com following the presentation.

See the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=914989

Leave a comment

Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), (Catalyst Pharmaceuticals), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported financial results for the first quarter ended March 31, 2015.

“This quarter we have been working to advance regulatory and commercial affairs and are moving closer to initiating the submission of our rolling NDA to the FDA next quarter for Firdapse® for the symptomatic treatment of LEMS,” said Patrick J. McEnany, Catalyst’s Chief Executive Officer. “This past quarter we made important strides on our commercial infrastructure, significant progress with our pipeline, and also strengthened our cash position.”

Read the full text here: http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=912411

Leave a comment
Follow

Get every new post delivered to your Inbox.

Join 259 other followers

%d bloggers like this: